P123 Common troublesome symptoms and their impact on health-related quality of life (QoL) in 359 patients with myelodysplastic syndromes (MDS): results of an internet-based survey

Steensma, David P.; Heptinstall, Kathleen; Johnson, Victoria; Novotny, Paul J.; Sloan, Jeff A.; Camoriano, John; Niblack, Joyce; Bennett, J.M.; Mesa, Ruben A.

doi:10.1016/s0145-2126(07)70193-5

Leukemia Research

2007

DOI: 10.1016/s0145-2126(07)70193-5

|View full text |Cite

P123 Common troublesome symptoms and their impact on health-related quality of life (QoL) in 359 patients with myelodysplastic syndromes (MDS): results of an internet-based survey

David P. Steensma¹,

Kathleen Heptinstall²,

Victoria Johnson³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

2009

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Refractory anemia in myelodysplastic syndromes (MDS) is a well established clinical hallmark observed in the vast majority of patients. Despite the availability of 3 therapeutic agents approved for the treatment of MDS by the United States Food and Drug Administration (FDA) (lenalidomide, 5‐azacytidine and decitabine), for the majority of patients, erythropoietin continues to be the initial choice of treatment 1. Recombinant human erythropoietin or epoetin α (EPO) was the first and had remained the most widely used erythropoiesis‐stimulating agent (ESA) in MDS since the early 1990s.…”

mentioning

confidence: 99%

An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte– or granulocyte‐macrophage–colony‐stimulating factor in myelodysplastic syndromes using a meta‐analysis approach

Mundle

Lefèbvre

Vekeman

et al. 2009

Cancer

View full text Add to dashboard Cite

BACKGROUND: Epoetin α (EPO) continues to be the initial treatment of choice for most anemic patients with myelodysplastic syndromes (MDS). Over the years, different therapeutic strategies have been adopted to optimize the clinical benefits of EPO in this setting. METHODS: In the current meta‐analysis of published literature, erythroid response (ER) rates with EPO as a single agent versus its combination with granulocyte–colony‐stimulating factor (G‐CSF) or granulocyte‐macrophage–colony‐stimulating factor (GM‐CSF) were compared. RESULTS: The assessment indicated that the ER rates were comparable between the 2 EPO‐based therapeutic strategies. Furthermore, EPO monotherapy at a higher dose of 60,000 to 80,000 U weekly produced significantly higher ER rates (64.5%) compared with the standard oncology dose of 30,000 to 40,000 U weekly either as a single agent (49%; P < .001) or in combination with G‐CSF/GM‐CSF (50.6% P = .007). In addition, when transfusion‐dependent patients were assessed separately, both EPO monotherapy and its combination with G‐CSF/GM‐CSF produced comparable and appreciable levels of transfusion independence (28.8% and 24.8%, respectively). CONCLUSIONS: In the current meta‐analysis, higher doses of EPO demonstrated better ER rates compared with EPO at standard doses alone or in combination with G‐CSF/GM‐CSF. Furthermore, the authors concluded that prospective clinical studies are warranted to evaluate the use of higher doses of EPO in anemic patients with MDS. Cancer 2009. © 2009 American Cancer Society.

show abstract

mentioning

confidence: 99%

An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte– or granulocyte‐macrophage–colony‐stimulating factor in myelodysplastic syndromes using a meta‐analysis approach

Mundle

Lefèbvre

Vekeman

et al. 2009

Cancer

View full text Add to dashboard Cite

show abstract

Erythropoiesis-Stimulating Agents Versus Rbc Transfusion In Mds: Comparison of Long-Term Outcomes

Mundle

2007

Future Oncol.

View full text Add to dashboard Cite

Impaired erythropoiesis and refractory anemia are clinical hallmarks of the myelodysplastic syndromes (MDS). As the disease evolves, a steady decline in hemoglobin in these disorders invariably results in dependence on packed red blood cell (PRBC) transfusion. Such chronic transfusion dependence has been associated with iron overload causing cardio–hepatic toxicity and alloimmunization, and can result in reduced survival in these patients. The use of hematopoietic growth factors, particularly erythropoiesis-stimulating agents (ESAs), has been reported to reduce the need for PRBC transfusion, raise hemoglobin and improve quality of life, at least in patients responding to such a therapy. Importantly, the clinical benefits of ESA are well balanced, with an apparently favorable safety profile in MDS, thus providing an eminent therapeutic option to delay or avoid transfusion dependence in these patients. The present report provides a detailed comparative profile of long-term PRBC transfusions and the balance of clinical benefits versus risks associated with ESA therapy for MDS.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P123 Common troublesome symptoms and their impact on health-related quality of life (QoL) in 359 patients with myelodysplastic syndromes (MDS): results of an internet-based survey

Cited by 2 publications

References 0 publications

An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte– or granulocyte‐macrophage–colony‐stimulating factor in myelodysplastic syndromes using a meta‐analysis approach

An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte– or granulocyte‐macrophage–colony‐stimulating factor in myelodysplastic syndromes using a meta‐analysis approach

Erythropoiesis-Stimulating Agents Versus Rbc Transfusion In Mds: Comparison of Long-Term Outcomes

Contact Info

Product

Resources

About